Relypsa, a Vifor Pharma Group company, aims to focus in iron deficiency, nephrology and cardio-renal therapeutic areas. We strive to help improve the lives of patients with severe and chronic diseases. Veltassa® (patiromer) for oral suspension is a calcium-based potassium binder indicated for the treatment of hyperkalemia. This virtual booth is ONLY for requesting Veltassa-related information by a US healthcare professional, and not for reporting information about any medication side effects. To report adverse reactions, contact Relypsa, Inc. at 1-844-735-9772.